COV
CLEO DIAGNOSTICS LTD
$0.2900
▼ -1.69%
Market cap
$41M
Turnover
$49,911
Last price
$0.2900
Day change
-1.69%
Announcements
11
Range, past year
Open 0.350 · Low 0.270 · Now 0.290 · High 0.900
Open COV in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
COV momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
27/100
Wyckoff phase
Downtrend12d
Trend stage
Breakdown
1 Day
-1.7%
1 Week
-3.3%
1 Month
-15.9%
1 Year
-23.7%
RSI
39
Avg daily range
8.4%
CLEO DIAGNOSTICS LTD scores 27 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 12 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -43.1%
- High volatility (ATR 8.4%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCOV announcements
Recent price-sensitive releases.
- 2026-09-24 CLEO Commences Ovarian Cancer Screening Test Development Progress Report
- 2026-09-10 CLIA Certified Lab selected - Pivotal US Clinical Validation Progress Report
- 2026-09-03 CLEO Receives First Batch of Commercial Test Kits Progress Report
- 2026-08-20 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-29 Quarterly activities and cashflow report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-13 CLEO Enters Analytical Validation Phase
- 2026-05-20 CLEO Establishes U.S. Reimbursement Pathway
More Health Care stocks
Most traded in the same sector.